⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

JUBLPHARMA - Fundamental Analysis: Financial Health & Valuation

Back to List

Rating: 3.2

Last Updated Time : 19 Mar 26, 07:10 pm

Fundamental Rating: 3.2

Stock Code JUBLPHARMA Market Cap 13,580 Cr. Current Price 851 ₹ High / Low 1,250 ₹
Book Value 141 ₹ Dividend Yield 0.58 % ROCE 2.91 % ROE 1.04 %
Face Value 1.00 ₹ DMA 50 916 ₹ DMA 200 1,009 ₹ Chg in FII Hold -0.60 %
Chg in DII Hold 0.70 % PAT Qtr 6.60 Cr. PAT Prev Qtr -48.0 Cr. RSI 45.4
MACD -26.8 Volume 84,305 Avg Vol 1Wk 1,81,761 Low price 784 ₹
High price 1,250 ₹ Debt to equity 0.02 52w Index 14.4 % Qtr Profit Var 154 %
EPS 1.23 ₹ Industry PE 27.6

📊 Core Financials

  • Revenue Growth: PAT turned positive (₹6.6 Cr vs -₹48 Cr), but remains weak
  • Profit Margins: Very low with ROE at 1.04% and ROCE at 2.91%
  • Debt Ratios: Debt-to-Equity at 0.02, virtually debt-free
  • Cash Flows: Dividend yield of 0.58% provides modest shareholder returns
  • Return Metrics: Efficiency far below industry peers

💹 Valuation Indicators

  • P/E Ratio: Not meaningful due to low EPS
  • P/B Ratio: ~6.0 (Price ₹851 / Book Value ₹141, trading at a premium)
  • PEG Ratio: Not available, growth outlook uncertain
  • Intrinsic Value: Appears stretched given weak profitability

🏢 Business Model & Competitive Advantage

  • Operates in pharmaceuticals under Jubilant Group
  • Competitive advantage lies in diversified pharma portfolio and group backing
  • Weak profitability metrics limit sustainability despite scale

📈 Entry Zone Recommendation

  • Current Price: ₹851
  • Support Zone: ₹784 – ₹820 (near 52-week low, RSI at 45.4 indicates weak momentum)
  • Long-term Holding: Risky due to weak returns and stretched valuation; suitable only for speculative investors betting on turnaround

✅ Positive

  • Debt-free balance sheet (Debt-to-Equity 0.02)
  • Dividend yield of 0.58% adds shareholder value
  • DII holdings increased (+0.70%), showing domestic investor confidence

⚠️ Limitation

  • ROE and ROCE very weak compared to peers
  • P/B ratio high, suggesting overvaluation
  • P/E not meaningful due to low EPS

📉 Company Negative News

  • Quarterly PAT remains very low despite improvement
  • FII holdings decreased (-0.60%), showing reduced foreign investor confidence
  • Technical indicators (MACD negative, RSI weak) reflect bearish momentum

📈 Company Positive News

  • Quarterly PAT improved significantly (₹6.6 Cr vs -₹48 Cr)
  • DII holdings increased, reflecting domestic institutional support

🌐 Industry

  • Pharmaceutical industry benefits from global healthcare demand
  • Industry P/E at 27.6 highlights JUBLPHARMA trading at a steep premium despite weak earnings

🔎 Conclusion

JUBLPHARMA shows signs of recovery with PAT turning positive and a debt-free balance sheet, but profitability remains weak and valuations are stretched. Entry around ₹784–₹820 may provide a safer margin for speculative investors. Long-term holding requires caution until earnings stabilize and return ratios improve, though group backing provides strategic strength.

NIFTY 50 - Fundamental Stock Watchlist

NEXT 50 - Fundamental Stock Watchlist

MIDCAP - Fundamental Stock Watchlist

SMALLCAP - Fundamental Stock Watchlist